Pre-made Imsidolimab benchmark antibody ( Whole mAb, anti-IL36R/IL1RL2 therapeutic antibody, Anti-IL1RRP2/IL-1Rrp2/IL1R-rp2 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-269
Pre-Made Imsidolimab biosimilar, Whole mAb, Anti-IL36R/IL1RL2 Antibody: Anti-IL1RRP2/IL-1Rrp2/IL1R-rp2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which we are initially developing as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis (GPP), EGFRi-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Imsidolimab biosimilar, Whole mAb, Anti-IL36R/IL1RL2 Antibody: Anti-IL1RRP2/IL-1Rrp2/IL1R-rp2 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Generalised pustular psoriasis;Localised pustular psoriasis|